Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

被引:73
|
作者
Azizi, Fereidoun [1 ]
Amouzegar, Atieh [1 ]
Tohidi, Maryam [2 ]
Hedayati, Mehdi [3 ]
Khalili, Davood [2 ,4 ]
Cheraghi, Leila [4 ]
Mehrabi, Yadollah [5 ]
Takyar, Miralireza [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, POB 19395-4763, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Cellular & Mol Endocrine Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Epidemiol & Biostat, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol & Biostat, Tehran, Iran
关键词
long-term; methimazole; Graves' disease; remission rates; ANTITHYROID DRUG-TREATMENT; HYPERTHYROIDISM; EXPOSURE; IODINE; RISK;
D O I
10.1089/thy.2019.0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 +/- 22 months in long-term patients and 19 +/- 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
收藏
页码:1192 / 1200
页数:9
相关论文
共 50 条
  • [41] A randomized, douuble-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine
    Lémann, M
    Mary, JY
    Colombel, JF
    Duclos, B
    Soule, JC
    Lerebours, E
    Modigliani, R
    Bouhnik, Y
    GASTROENTEROLOGY, 2005, 128 (07) : 1812 - 1818
  • [42] Long-Term Quit Rates After a Perioperative Smoking Cessation Randomized Controlled Trial
    Lee, Susan M.
    Landry, Jennifer
    Jones, Philip M.
    Buhrmann, Ozzie
    Morley-Forster, Patricia
    ANESTHESIA AND ANALGESIA, 2015, 120 (03): : 582 - 587
  • [43] Graves' disease in children: long-term outcomes of medical therapy
    Rabon, Shona
    Burton, Amy M.
    White, Perrin C.
    CLINICAL ENDOCRINOLOGY, 2016, 85 (04) : 632 - 635
  • [44] A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care
    Politis, AM
    Vozzella, S
    Mayer, LS
    Onyike, CU
    Baker, AS
    Lyketsos, CG
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (11) : 1087 - 1094
  • [45] LONG-TERM REMISSION IN HODGKINS DISEASE AFTER NITROGEN MUSTARD THERAPY - REPORT OF A CASE
    KIELY, JM
    HARRISON, EG
    CANCER, 1970, 26 (04) : 800 - &
  • [46] Long-term results of irradiation for patients with progressive Graves' ophthalmopathy
    Marquez, SD
    Lum, BL
    McDougall, IR
    Katkuri, S
    Levin, PS
    MacManus, M
    Donaldson, SS
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03): : 766 - 774
  • [47] THYROID-STIMULATING ANTIBODIES IN PATIENTS WITH LONG-TERM REMISSION OF GRAVES HYPERTHYROIDISM
    HORMANN, R
    HOBELSBERGER, A
    SALLER, B
    MANN, K
    KLINISCHE WOCHENSCHRIFT, 1986, 64 (21): : 1097 - 1100
  • [48] Long-term results after surgical therapy of Crohn's disease
    Lauschke, H
    Kaminski, M
    Wiedwald, C
    Tolba, R
    Hirner, A
    ZENTRALBLATT FUR CHIRURGIE, 2002, 127 (08): : 706 - 711
  • [49] Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
    Papamichael, Konstantinos
    Casteele, Niels Vande
    Gils, Ann
    Tops, Sophie
    Hauenstein, Scott
    Singh, Sharat
    Princen, Fred
    Van Assche, Gert
    Rutgeerts, Paul
    Vermeire, Severine
    Ferrante, Marc
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (06) : 1103 - 1110
  • [50] LONG-TERM CLINICAL TRIAL OF INTRAVENOUS THERAPY OF ASCITES IN PATIENTS WITH CIRRHOSIS
    CLERMONT, RJ
    VLAHCEVI.ZR
    ADHAM, NF
    MORRISON, RS
    MOORE, EW
    CHALMERS, TC
    GASTROENTEROLOGY, 1965, 48 (06) : 810 - &